Crescita Therapeutics Inc.

Total Valuation

Crescita Therapeutics Inc. carries a market capitalization of 14.71M, placing it among publicly traded companies globally. Its enterprise value stands at 7.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Crescita Therapeutics Inc. currently has 18.61M shares outstanding.

Valuation Ratios

Crescita Therapeutics Inc. trades at a trailing price-to-earnings ratio of 14.76. The price-to-sales ratio is 0.60, and the price-to-book ratio stands at 2.85.

Enterprise Valuation

On an enterprise value basis, Crescita Therapeutics Inc. trades at an EV/EBITDA multiple of 20.81 and an EV/FCF ratio of 3.71.

Financial Position

Crescita Therapeutics Inc. maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.34, indicating elevated leverage, while an interest coverage ratio of 6.17 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Crescita Therapeutics Inc.'s stock has gained approximately 62.8866% over the past 52 weeks. The 50-day moving average sits at 0.75, while the 200-day moving average is 0.55.

Income Statement

Over the trailing twelve months, Crescita Therapeutics Inc. generated 23.22M in revenue and converted that into -320,000.00 in net income, yielding earnings per share of -0.02. EBITDA reached 370,000.00, while operating income came in at -1.16M.

Balance Sheet

Crescita Therapeutics Inc. holds 8.71M in cash and equivalents against 2.50M in total debt, resulting in a net debt position of -8.71M. Total book value stands at 4.89M, with working capital of 10.17M providing operational flexibility.

Cash Flow

Crescita Therapeutics Inc. produced 1.73M in operating cash flow over the past twelve months. After subtracting -285,000.00 in capital expenditures, free cash flow totaled 1.44M - equivalent to 0.08 per share.

Margins

Crescita Therapeutics Inc. operates with a gross margin of 51.71, reflecting its pricing power and cost economics. The operating margin of -5.02 and net profit margin of -1.38 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Crescita Therapeutics Inc.'s most recent stock split took place on February 6, 2018 with a 200:209 split ratio.

Scores

Crescita Therapeutics Inc. posts an Altman Z-Score of -0.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.